David Charles Lubner
CIK 1572000 · Executive VP and CFO · last filed 2026-06-09
David Charles Lubner is an Executive VP and CFO who has filed 55 SEC Form 4 insider transactions across 10 companies since 2013. The most recent filing, for DYN, was dated Jun 9, 2026. Across all open-market trades the lifetime net is −$2.8M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
10
55
-$2.78M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DYN | Director | 0 | $18.19 | $0 | $0 | 9 | 2026-06-09 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | — | $15.70 | — | $0 | 2 | 2026-06-03 |
| Arcellx, Inc. (ACLX) Delisted | Director | 0 | $115.07 | $0 | -$450.0K | 7 | 2026-04-28 |
| CARGO Therapeutics, Inc. (CRGX) Delisted | Director | — | $4.47 | — | $0 | 4 | 2025-08-19 |
| VOR | Director | — | $14.36 | — | $0 | 5 | 2025-05-23 |
| POINT Biopharma Global Inc. (PNT) Delisted | Director | 3,600 | $12.50 | $45.0K | $24.7K | 5 | 2023-12-27 |
| Disc Medicine, Inc. (GMTX) Delisted | Director | — | $13.50 | — | $0 | 5 | 2022-03-09 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Executive VP and CFO | 0 | — | — | $0 | 5 | 2020-04-03 |
| NITE | Director | 0 | $37.45 | $0 | $0 | 2 | 2019-06-07 |
| TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | SVP and CFO | 78,770 | — | — | -$2.35M | 11 | 2015-08-17 |
Recent Filings
55 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-09 | DYN | Grant (A) | — | $0 | EDGAR |
| 2026-06-03 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2026-04-28 | Arcellx, Inc. (ACLX) Delisted | Mixed | −21,659 | $0 | EDGAR |
| 2026-04-28 | DYN | Gift (G) | −53,625 | $0 | EDGAR |
| 2026-01-20 | Arcellx, Inc. (ACLX) Delisted | Mixed | — | -$412.3K | EDGAR |
| 2025-08-19 | CARGO Therapeutics, Inc. (CRGX) Delisted | Disp (D) | — | $0 | EDGAR |
| 2025-06-23 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-06-20 | CARGO Therapeutics, Inc. (CRGX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-06-03 | DYN | Grant (A) | — | $0 | EDGAR |
| 2025-05-30 | Arcellx, Inc. (ACLX) Delisted | Grant (A) | — | $0 | EDGAR |